0
The Zendal Group has finalised an agreement for the acquisition of the Catalan pharmaceutical company Maymo. This operation is for 100% of the company, completing a process that the Galician group began in 2022 with the purchase of 46% of the shares of Maymo (Laboratorios Maymo, S.A.).
This new business activity brings the number of companies integrated under the umbrella of the Zendal group, based in O Porrino (Galicia) to eight. The distinct divisions allow it to develop various projects focused on the research, development and manufacture of biologic and pharmaceutical products for both animal and human health, as vaccinology and probiotics play an essential role across the entire portfolio, in line with the advances in modern-day science.
The synergies of both portfolios, as well as the client growth of both companies, will place Zendal in a fantastic position in the animal health sector. This growth also reinforces the work carried out by the Galician group with Laboratorios Ovejero (Leon), which became part of the corporation, led by Andrés Fernandez, in 2021.
Maymo has a 16,000 m2 site in Castellbisbal (Barcelona) where they produce medicines for production animals in various pharmaceutical forms, including injectables, oral solutions, nutrition and disinfectants.
Thus, through this new incorporation, Zendal aims to consolidate the market position of its animal health division, in both the national and international markets. This is a key objective within its strategic plan, that includes the growth of its portfolio. In keeping with the One Health philosophy, this area is destined to increase, since it has been shown that animal welfare and the protection of ecosystems are intrinsically linked to human health.
Strategic positioning
This operation allows the Zendal Group to consolidate its role as a market leader on the Iberian Peninsula with manufacturing plants in O Porrino (Galicia), Leon (Castilla-Leon) and Barcelona (Catalonia) and one that will open this year in Paredes de Coura (Portugal).
The group has increased its production capacity significantly over the last two years and with the plant in Portugal coming on-line soon, Zendal will also have greater potential for the development of new vaccine projects.
Presence in 25 countries
Laboratorios Maymo, S.A. is a family business founded in 1929 by Dr. Josep Maymo. Operating in more than 25 countries, Maymo specializes in animal health, developing, manufacturing and marketing numerous pharmaceutical products for veterinary use.
In 2006 it acquired Laboratorios e Industrias Iven, S.A., a Madrid-based company that markets its proprietary veterinary pharmaceutical products.
The Maymo family will maintain a presence in the group, their invaluable professional experience will contribute to the integration process and future development of the group.
February 28, 2023 - Zendal Group
